atrial fibrilation

Showing 10 posts of 10 posts found.

Merck drops oral anticoagulant

March 25, 2011
Merck, Pradaxa, Xarelto, anticoagulant, atrial fibrilation, vorapaxar

Merck has given the rights to its oral anticoagulant betrixaban back to Portola Pharmaceuticals after a review of its late …

Sanofi-Aventis' Multaq (dronedarone)

FDA issues Multaq liver warning

January 17, 2011
Sales and Marketing FDA, Multaq, atrial fibrilation, dronedarone

US regulators have warned doctors and patients about the risk of severe liver injury associated with Sanofi-Aventis’ atrial fibrillation (AF) …

FDA approves Boehringer’s Pradaxa

October 20, 2010
Sales and Marketing Boehringer, Pradaxa, atrial fibrilation

Boehringer Ingelheim’s Pradaxa has stolen a march over its rivals by being the first new oral anticoagulant to reach the …


FDA committee backs Pradaxa

September 23, 2010
Sales and Marketing Boehringer, Pradaxa, atrial fibrilation

An FDA committee has voted unanimously in favour of approving Pradaxa for stroke prevention in patients with atrial fibrillation. The …

Multaq tablets

Sanofi’s Multaq in pole position for AF market

September 6, 2010
Sales and Marketing Multaq, Sanofi-Aventis, atrial fibrilation

New European Society of Cardiology guidelines on treating atrial fibrillation (AF) include a recommendation for Sanofi-Aventis’ Multaq. The endorsement is …

Pradaxa, Xarelto and apixaban vie for attention

September 6, 2010
Research and Development, Sales and Marketing Pradaxa, Xarelto, apixaban, atrial fibrilation

New data has intensified the competition between three rival would-be cardiology blockbusters. Boehringer Ingelheim’s Pradaxa (dabigatran) and Bayer’s Xarelto (rivaroxaban) …

Novel anticoagulants set to lead atrial fibrillation market

July 9, 2010
Sales and Marketing Brinavess, Multaq, Pradaxa, Xarelto, apixaban, atrial fibrilation

Novel anticoagulants set to capture the atrial fibrillation market by 2019, according to a new report. Analysts Decision Resources say …

New anti-clotting drugs: stopping the silent killers

June 28, 2010
Research and Development, Sales and Marketing Pradaxa, VTE, Xarelto, atrial fibrilation, thrombosis

Blood clots are a major killer, but the threat they pose is poorly understood by the general public compared to …

Early halt for successful apixaban trial

June 14, 2010
Research and Development apixaban, atrial fibrilation

Pfizer and Bristol-Myers Squibb’s atrial fibrillation treatment apixaban has performed so well in a phase III trial that it has …

Merck’s Brinavess performs in phase III

May 18, 2010
Research and Development Brinavess, Merck & Co, atrial fibrilation

Merck & Co’s heart disorder drug Brinavess has proved superior to rival amiodarone in reducing rates of atrial fibrillation in …

Latest content